JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Last updated: 01 November 2019
Rubraca (rucaparib), already approved as a treatment for BRCA positive ovarian cancer, has been approved as a maintenance therapy for ovarian cancer regardless of BRCA mutation. Read more
